Pharmaceutical Products

The Ares Specialty Healthcare Fund is a specialized direct‑lending vehicle managed by Ares Management, formed to provide flexible capital solutions to companies operating across the specialty healthcare ecosystem. It focuses on industries such as pharmaceuticals, biotechnology, medical technologies and diagnostics, specialist healthcare services and healthcare IT where companies often face constraints accessing traditional bank financing or need transformational capital. The fund is structured to invest across the capital structure — from first‑ and second‑lien senior secured loans, to mezzanine debt, preferred equity and minority equity stakes — enabling the team to tailor solutions to companies undergoing growth or transformation. It targets businesses in North America and Europe and is backed by a dedicated investment team and industry advisory board with deep healthcare operating expertise. Recognising enduring structural trends — an aging population, innovation in diagnostics and medtech, increasing digitalisation of healthcare and shifting service models — the fund seeks to invest in companies with resilient demand and growth potential. It aims to deliver both defensive characteristics (i.e., non‑cyclical healthcare demand) and meaningful upside from innovation and transformation in the healthcare value chain. By partnering with firms across the healthcare spectrum — from device manufacturers and diagnostics players to niche specialty services and healthcare IT platforms — the fund aims to fill a financing gap and support businesses that are scaling, executing roll‑ups or transforming their offerings. The strategy leverages Ares’ broader credit platform and healthcare expertise to structure creative, non‑dilutive capital solutions in an increasingly competitive healthcare financing environment.

BluePeak Private Capital Fund II (BPCF II) is a pan-African private credit fund launched by BluePeak Private Capital, an alternative asset management firm established in 2019. The fund aims to raise $250 million to provide flexible credit solutions to underserved mid-sized businesses across Africa, addressing the persistent financing gap that hinders their growth. BPCF II focuses on delivering impact-driven investments while offering investors superior risk-adjusted returns. The fund targets strategic sectors such as manufacturing, pharmaceuticals, logistics, and financial services—industries pivotal to deepening local value chains and fostering industrial clusters. With a strong emphasis on gender inclusion, BPCF II is 2X Challenge qualified, promoting women's economic empowerment as a core objective. The fund integrates sustainability considerations throughout its investment process, prioritizing resilience, inclusive growth, and long-term value creation. In its first close, BPCF II secured $80 million in commitments from leading European Development Finance Institutions (DFIs), including British International Investment (BII), FMO, Swedfund, and the Swiss Investment Fund for Emerging Markets (SIFEM). These commitments underscore the DFIs' confidence in BluePeak's strategy to combine performance with impact, mobilizing capital to Africa's underserved mid-market segment.

CVC Strategic Opportunities II is a €4.6 billion private equity fund launched in 2019 by CVC Capital Partners. It is the second fund in CVC’s long-dated investment strategy, focusing on patient capital for high-quality businesses. The fund emphasizes long-term partnerships with companies operating in low-volatility sectors and demonstrating strong cash flow generation. The strategy targets control, co-control, or significant minority stakes in companies offering essential products or services. These businesses typically have stable capital structures and consistent earnings. CVC works with portfolio companies to enhance value through operational improvements and strategic growth initiatives. The fund primarily focuses on Western Europe and North America, investing across sectors such as commercial services, pharmaceuticals, biotechnology, and manufacturing. Target companies generally have enterprise values between €1 billion and €5 billion, allowing CVC to support a broad range of sizable, stable businesses.

Columbus Life Sciences Fund IV is a venture capital fund based in Spain and managed by Columbus Venture Partners. The fund has a size of 150 million euros and it is aimed at biotechnology and pharmaceutical startups. The portfolio of companies selected for this fund will focus on disruptive treatments and industrial development, particularly in the drug development process. The fund plans to make between ten and twelve investments in total. Investments from this fund will range from three million euros to a maximum of twenty million euros over the life cycle of the company. The investment timeframe for selecting portfolio companies is up to three years, with a total period of ten years to close. The Columbus VP team, led by founders and managing partners Javier García and Damià Tormo, along with partners Julen Oyarzábal, José Mesa, and Robert Armstrong, will manage this new fund.

The fund is the fourth flagship vehicle from GHO Capital, leveraging its deep specialization in healthcare to back companies delivering better, faster and more accessible care. With its final close at over €2.5 billion, the vehicle is positioned to scale high‑growth businesses across services, medtech, diagnostics and health‑tech platforms. GHO Capital IV focuses on companies where strong management, operational improvement and international expansion can unlock significant value. The fund partners with leadership teams in niche but growing healthcare subsectors and applies the firm’s sector insight, global network and operational resources to drive transformation. The strategy targets enterprises that serve pharmaceutical, biotechnology and medical device customers — such as CDMOs, contract services, outsourcing platforms, diagnostics manufacturers and digital health enablers — where structural tailwinds and under‑penetrated markets offer runway for growth. Geographically, the fund emphasises Europe and North America but retains flexibility to leverage cross‑border dynamics, enabling portfolio companies to scale internationally. Through disciplined buy‑outs, add‑on consolidation and operational acceleration, GHO Capital IV aims to d

Gyrus Capital, a Geneva-based private equity firm specializing in healthcare and sustainability sectors, has successfully closed a €700 million single-asset continuation fund dedicated to Essential Pharma. Essential Pharma is an international specialty pharmaceutical group focused on providing access to low-volume, clinically differentiated, niche pharmaceutical products across key therapeutic areas. The continuation fund was led by AlpInvest Partners, a subsidiary of Carlyle Global Investment Solutions, with significant participation from StepStone Group and other new and existing investors. Both Gyrus Capital and Essential Pharma's management team have made meaningful reinvestments in the fund. This transaction provides Essential Pharma with substantial additional capital to expand its diversified portfolio of established and rare disease medicines through acquisitions and development strategies. The company operates globally in more than 70 countries, supplying over 300 products across multiple therapeutic areas.

The $750 million private equity multi-asset continuation fund announced by Hildred Capital is focused on healthcare and specializes in partnering with middle-market companies. The fund was structured to align the interests of the general partnership and limited partners, with the co-founders rolling over 100% of their economic interests into the continuation fund. Limited partners had the option to roll all, sell all, or sell a portion of their interests and roll a portion into the continuation fund. This fund aims to provide additional committed capital for companies to execute organic growth initiatives, pursue strategic acquisitions, and continue to drive operating leverage. It has generated significant liquidity and attractive returns for selling limited partners while also providing new investors with the opportunity to participate over time in the appreciation of strong and growing companies.

Iron Wolf Capital has announced the first close of its second fund, securing $32.7 million with a target of $109 million. The fund focuses on early-stage investments in deeptech and AI startups across the Baltic region and its diaspora. Initial investments range from $545,000 to $2.18 million, with the firm often leading or co-leading funding rounds. The firm is recognized as one of the most active investors in the Baltics, having supported over 20 companies in the past five years. Its portfolio spans various sectors, including robotics, photonics, AI-driven education technology, pharmaceuticals, and climate technology. Iron Wolf Capital emphasizes backing exceptional founders with global ambitions and disruptive technologies. Beyond capital, Iron Wolf Capital contributes to the ecosystem through initiatives like the Baltic Deep Tech Report and the Deep Tech Breakfast Series, fostering collaboration and growth within the region's innovation landscape.

Linden Capital Partners, a Chicago-based private equity firm specializing in healthcare, has successfully closed its sixth buyout fund, Linden Capital Partners VI, at $5.4 billion. This marks a major milestone, surpassing its $4.5 billion target and initial $5.0 billion hard cap. The fund secured $5.2 billion in LP commitments from investors in more than 20 countries, along with a $200 million general partner commitment. Fund VI will continue Linden’s long-standing strategy of investing in middle-market healthcare companies, with a focus on services, products, and distribution segments. The firm brings a disciplined approach to value creation, combining deep operational expertise, tailored growth strategies, and a unique human capital model to support long-term success. The fund's investor base includes major institutional investors such as the New York State Teachers’ Retirement System, Texas County & District Retirement System, Louisiana State Employees’ Retirement System, Sacramento County Employees’ Retirement System, and Fairfax County Educational Employees’ Supplementary Retirement System. The oversubscribed fund closed in under nine months, highlighting strong investor demand and Linden’s leadership in healthcare investing.

Quadria Capital Fund III is a growth-stage private equity vehicle focused on transforming healthcare systems across South and Southeast Asia. With $1.07 billion in commitments, the fund aims to build a diversified portfolio of approximately 10 market-leading companies, taking both significant minority and majority stakes. The fund has already deployed nearly 40% of its capital, including investments in Aragen Life Sciences, NephroPlus, and Maxivision Eye Hospital.The fund targets sectors such as healthcare delivery, life sciences, medical technology, and associated healthcare services. It seeks to invest in companies that provide high-quality, affordable healthcare solutions, leveraging technology and innovation to address the growing demand in the region. Quadria Capital's strategy includes partnering with exceptional healthcare businesses to enhance their impact and scale, while generating superior returns for investors.Quadria Capital Fund III has attracted a diverse group of investors, including sovereign wealth funds, asset managers, strategic corporates, and impact investors from North America, Europe, the Gulf Cooperation Council, and Asia. The fund's focus on healthcare transformation aligns with the increasing need for accessible and affordable healthcare services in rapidly growing markets.

Vivo Opportunity Fund III is the latest iteration of Vivo Capital's evergreen equity fund, structured in three-year investment cycles. With over $740 million in commitments, the fund continues its focus on small- and mid-cap biotechnology and life sciences companies, particularly those developing or commercializing novel therapies targeting unmet medical needs. The fund primarily backs preclinical and clinical-stage companies, aiming to realize value through scientific breakthroughs and pivotal clinical milestones. Vivo Capital employs a hybrid strategy that combines public market investing with a venture capital approach, leveraging the firm’s technical expertise to identify high-potential healthcare assets. Vivo has a strong track record, with previous Opportunity Funds supporting companies that have reached major inflection points, such as FDA approvals or strategic acquisitions. Noteworthy examples include investments in Verona Pharmaceuticals, Geron Corporation, and Soleno Therapeutics.